Article Details
Retrieved on: 2019-03-15 00:52:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Sorrento Therapeutics, Inc. (NASDAQ:SRNE), with a trailing 12-month price-to-sales ratio of 8.61, is now among the bigger bargains in its industry.</div>
Article found on:
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here